Nasdaq
$7.39▲ 1.93%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $400.1MShares out 54.1M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
6- 2d agoPre-market26.10.23 22:158-KKey event#●●●#●●●#●●●
Eikon Therapeutics, Inc.Bullish
Eikon Therapeutics presented clinical data for its PARP1 inhibitors EIK1003 and EIK1004, and WRN helicase inhibitor EIK1005 at the 2026 ESMO Congress. EIK1003 demonstrated clinical activity and tolerability in monotherapy and combination settings, while EIK1004 and EIK1005 showed promising safety and preliminary efficacy signals. The company expects to report further clinical results throughout 2027.…more
$7.39+1.93%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.7Regular26.10.08 00:47SCHEDULE 13G/AOwnership
Eikon Therapeutics, Inc.
FMR LLC, its affiliates, and Abigail P. Johnson have jointly filed a Schedule 13G regarding their beneficial ownership of Eikon Therapeutics, Inc. common stock. This filing reflects the ownership status as of September 30, 2026.…more
$7.39+1.93%vs prev closeView filingShare - 10.2Regular26.10.03 00:14SCHEDULE 13G/AOwnership
Eikon Therapeutics, Inc.
The Abu Dhabi Investment Authority has filed a SCHEDULE 13G/A regarding its beneficial ownership in Eikon Therapeutics, Inc. This filing serves as an update to the investor's significant stake in the company.…more
$7.39+1.93%vs prev closeView filingShare
5 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoPre-market26.10.23 22:15#●●●#●●●
Eikon Therapeutics Presents Clinical Data for Oncology Pipeline at ESMO…more
Eikon Therapeutics presented initial and updated clinical data for its PARP1 and WRN helicase inhibitor candidates at the ESMO Congress. While the results demonstrate safety and preliminary antitumor activity, the programs remain in early-stage clinical development.…more
$7.39+1.93%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 6d agoClosed26.10.19 07:05
●●●●●●●● ●●●●● ●●●●●●
Eikon Therapeutics will present updated clinical data for four of its drug candidates at the upcoming European Society for Medical Oncology (ESMO) Congress. These presentations highlight the progress of the company's oncology pipeline, though clinical efficacy remains to be fully validated.…more
$7.39+1.93%vs prev close - 10.15Pre-market26.10.15 21:06
●●●●●●●● ●●●●● ●●●●●●
Eikon Therapeutics has submitted an Investigational New Drug application to the FDA to evaluate its novel prostate cancer treatment, EIK1006. The candidate is a distinct androgen receptor antagonist structurally unrelated to existing lutamide-class therapies.…more
$7.39+1.93%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report